Prime Medicine, Inc. (PRME) — Operating Cash Flow
| Fiscal Year | Operating Cash Flow | Change YoY |
|---|---|---|
| 2025 | -$162.56M | -32.3% |
| 2024 | -$122.86M | +25.7% |
| 2023 | -$165.41M | -25.5% |
| 2022 | -$131.83M | -286.8% |
| 2021 | -$34.08M | -514.8% |
| 2020 | -$5.54M | — |
| Fiscal Year | Operating Cash Flow | Change YoY |
|---|---|---|
| 2025 | -$162.56M | -32.3% |
| 2024 | -$122.86M | +25.7% |
| 2023 | -$165.41M | -25.5% |
| 2022 | -$131.83M | -286.8% |
| 2021 | -$34.08M | -514.8% |
| 2020 | -$5.54M | — |